Page 29 - Read Online

Giliberti et al. J Transl Genet Genom 2024;8:340-54 https://dx.doi.org/10.20517/jtgg.2024.41 Page 354

NCT04040049&rank=1 [Last accessed on 19 Nov 2024]
72. Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol
Genet Metab 2018;123:416-27. DOI
73. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation
and management of chronic kidney disease. Kidney Int 2024;105:S117-314. DOI
74. O’Mahony C, Coats C, Cardona M, et al. Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease.
Europace 2011;13:1781-8. DOI
75. Weidemann F, Maier SK, Störk S, et al. Usefulness of an implantable loop recorder to detect clinically relevant arrhythmias in patients
with advanced Fabry cardiomyopathy. Am J Cardiol 2016;118:264-74. DOI
76. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system
involvement. Genet Med 2006;8:539-48. DOI
77. Politei JM, Bouhassira D, Germain DP, et al. Pain in Fabry disease: practical recommendations for diagnosis and treatment. CNS
Neurosci Ther 2016;22:568-76. DOI PubMed PMC
78. Mujagic Z, Keszthelyi D, Aziz Q, et al. Systematic review: instruments to assess abdominal pain in irritable bowel syndrome. Aliment
Pharmacol Ther 2015;42:1064-81. DOI
79. Hoffmann B, Schwarz M, Mehta A, Keshav S; Fabry Outcome Survey European Investigators. Gastrointestinal symptoms in 342
patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 2007;5:1447-53.
DOI PubMed
80. Svensson CK, Feldt-Rasmussen U, Backer V. Fabry disease, respiratory symptoms, and airway limitation - a systematic review. Eur
Clin Respir J 2015;2:26721. DOI PubMed PMC
81. Germain DP, Avan P, Chassaing A, Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing
loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet 2002;3:10. DOI PubMed PMC
82. Lidove O, Jaussaud R, Aractingi S. Dermatological and soft-tissue manifestations of Fabry disease: characteristics and response to
enzyme replacement therapy. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS.
Oxford: Oxford PharmaGenesis; 2006. PubMed
83. Paim-Marques L, de Oliveira RJ, Appenzeller S. Multidisciplinary management of Fabry disease: current perspectives. J Multidiscip
Healthc 2022;15:485-95. DOI